Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18973867 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | December 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18927756 | BENZOTRIAZOLE COMPOUND | October 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18832305 | PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM POLYAMIDE 6 COMPRISING FISHING NETS | July 2024 | March 2025 | Allow | 8 | 0 | 0 | No | No |
| 18651408 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | April 2024 | May 2025 | Allow | 13 | 0 | 0 | No | No |
| 18650894 | TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINE | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18650932 | TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINE | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18621266 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | March 2024 | June 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18607834 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | March 2024 | May 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18688914 | COUPLED UREA MELAMINE PRODUCTION WITH HP CO2 STRIPPING | March 2024 | July 2024 | Allow | 4 | 0 | 0 | No | No |
| 18592808 | RAS INHIBITORS | March 2024 | April 2025 | Allow | 13 | 2 | 0 | No | No |
| 18584520 | Benzodiazepine Derivatives as RSV Inhibitors | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18582548 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | February 2024 | March 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18444006 | Compounds for the Treatment of Alzheimer's Disease | February 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18430498 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18423596 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND A CDK4/6 INHIBITOR | January 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18410925 | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | January 2024 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18388776 | HETEROCYCLIC COMPOUNDS | November 2023 | April 2025 | Allow | 17 | 2 | 0 | No | No |
| 18236095 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | August 2023 | December 2024 | Allow | 16 | 1 | 0 | No | No |
| 18232435 | Compounds, Compositions and Methods | August 2023 | March 2025 | Allow | 19 | 2 | 0 | No | No |
| 18227561 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | July 2023 | April 2025 | Allow | 21 | 0 | 1 | No | No |
| 18359467 | SYNTHESIS OF OMECAMTIV MECARBIL | July 2023 | August 2024 | Allow | 13 | 0 | 0 | No | No |
| 18345686 | COMPOSITIONS AND METHODS FOR TREATING CANCER | June 2023 | June 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18343319 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | June 2023 | February 2025 | Allow | 20 | 1 | 1 | No | No |
| 18211314 | NLRX1 LIGANDS | June 2023 | November 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18209939 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | June 2023 | April 2024 | Allow | 10 | 0 | 0 | No | No |
| 18329681 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18326344 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | May 2023 | September 2024 | Allow | 16 | 2 | 0 | No | No |
| 18199275 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | May 2023 | October 2024 | Allow | 17 | 1 | 0 | No | No |
| 18306191 | TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF | April 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18181336 | MCL-1 INHIBITORS | March 2023 | July 2024 | Allow | 16 | 1 | 0 | No | No |
| 18181116 | MCL1 INHIBITORS | March 2023 | August 2024 | Allow | 17 | 1 | 0 | No | No |
| 18176335 | mTORC1 INHIBITORS | February 2023 | May 2024 | Allow | 14 | 0 | 0 | No | No |
| 18176362 | IRE1 SMALL MOLECULE INHIBITORS | February 2023 | April 2024 | Allow | 14 | 1 | 0 | No | No |
| 18111453 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | February 2023 | October 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18170319 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | February 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18162052 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | January 2023 | August 2024 | Allow | 18 | 1 | 0 | No | No |
| 18162250 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | January 2023 | February 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18161266 | RAS INHIBITORS | January 2023 | December 2023 | Allow | 10 | 0 | 0 | No | No |
| 18101362 | COMPOUND WITH ANTICANCER ACTIVITY | January 2023 | March 2024 | Allow | 14 | 1 | 0 | No | No |
| 18099311 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | January 2023 | June 2024 | Allow | 17 | 1 | 0 | No | No |
| 18098834 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | January 2023 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18149992 | METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION AND ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND DAILY DOSING | January 2023 | October 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18082195 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | December 2022 | November 2024 | Abandon | 23 | 0 | 1 | No | No |
| 18080973 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | December 2022 | November 2024 | Abandon | 23 | 1 | 0 | No | No |
| 18061822 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | December 2022 | February 2024 | Allow | 60 | 1 | 0 | No | No |
| 18058220 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | November 2022 | April 2025 | Allow | 28 | 1 | 1 | No | No |
| 18057589 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | November 2022 | October 2024 | Abandon | 23 | 0 | 1 | No | No |
| 18056227 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | November 2022 | February 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18052096 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | November 2022 | August 2024 | Allow | 21 | 1 | 0 | No | No |
| 18051762 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | November 2022 | June 2024 | Allow | 19 | 1 | 0 | No | No |
| 17976267 | Compounds for the Treatment of Cancer and Inflammatory Disease | October 2022 | July 2024 | Allow | 21 | 2 | 0 | No | No |
| 17973209 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | October 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17962938 | Compounds | October 2022 | October 2024 | Allow | 24 | 1 | 1 | No | No |
| 17959144 | N/O-Linked Degrons and Degronimers for Protein Degradation | October 2022 | August 2024 | Allow | 22 | 1 | 1 | No | No |
| 17931814 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | September 2022 | November 2024 | Allow | 26 | 2 | 0 | No | No |
| 17902432 | INHIBITORS OF THE MENIN-MLL INTERACTION | September 2022 | February 2025 | Allow | 30 | 1 | 1 | No | No |
| 17881222 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | August 2022 | August 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17872855 | METHODS OF PREVENTING CANCER METASTASIS | July 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17871201 | P2X4 RECEPTOR ANTAGONIST | July 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17870303 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | July 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17865192 | NOVEL HETEROCYCLIC COMPOUNDS | July 2022 | August 2023 | Allow | 13 | 1 | 0 | No | No |
| 17792741 | BENZO[5,6][1,4]DIOXINO[2,3-B]PYRIDINE COMPOUNDS USEFUL AS IRAK4 INHIBITORS | July 2022 | June 2025 | Allow | 36 | 1 | 0 | No | No |
| 17811050 | COMPOSITION FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARYDISEASE COMPRISING REGORAFENIB AS ACTIVE INGREDIENT | July 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17810922 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | July 2022 | October 2024 | Allow | 27 | 1 | 1 | No | No |
| 17843194 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | June 2022 | August 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17841046 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | June 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17841026 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | June 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17836060 | POLYMORPHIC FORMS OF METOPIMAZINE | June 2022 | August 2023 | Allow | 15 | 0 | 0 | No | No |
| 17833272 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | June 2022 | April 2024 | Allow | 22 | 1 | 0 | No | No |
| 17782244 | METHOD FOR PRODUCING LAUROLACTAM, DEVICE FOR SYNTHESIZING SAME, LAUROLACTAM COMPOSITION PRODUCED THEREBY, AND METHOD FOR PRODUCING POLYLAUROLACTAM USING SAME | June 2022 | June 2025 | Allow | 36 | 1 | 1 | No | No |
| 17828832 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | May 2022 | February 2024 | Allow | 20 | 1 | 1 | No | No |
| 17748484 | ADDITIVE FOR IMPARTING ULTRAVIOLET ABSORBENCY AND/OR HIGH REFRACTIVE INDEX TO MATRIX, AND RESIN MEMBER USING SAME | May 2022 | December 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17746038 | RIFAXIMIN | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17738370 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | May 2022 | December 2023 | Allow | 19 | 1 | 0 | No | No |
| 17735386 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | May 2022 | June 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17735258 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | May 2022 | November 2023 | Allow | 19 | 1 | 0 | No | No |
| 17733755 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | April 2022 | March 2024 | Allow | 22 | 2 | 0 | No | No |
| 17720472 | Inhibitors of Beta-Hydoxylase for Treatment of Cancer | April 2022 | June 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17719433 | URACIL DERIVATIVES AS TRPA1 INHIBITORS | April 2022 | July 2023 | Allow | 15 | 1 | 0 | No | No |
| 17715935 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | April 2022 | July 2024 | Allow | 27 | 2 | 0 | No | No |
| 17712541 | LYSYL OXIDASE INHIBITORS | April 2022 | March 2024 | Allow | 24 | 1 | 0 | No | No |
| 17710485 | NOOTKATONE DERIVATIVES AND METHODS OF USING THE SAME | March 2022 | December 2023 | Allow | 20 | 2 | 0 | No | No |
| 17709021 | PYRIDOPYRIMIDINONE COMPOUNDS | March 2022 | November 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17754118 | HETEROCYCLIC COMPOUND AND USE THEREOF | March 2022 | December 2023 | Allow | 21 | 2 | 0 | No | No |
| 17697275 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | March 2022 | February 2025 | Allow | 35 | 1 | 0 | No | No |
| 17692536 | 3-SUBSTITUTED PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS | March 2022 | March 2024 | Allow | 25 | 2 | 1 | No | No |
| 17691862 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | March 2022 | July 2024 | Allow | 28 | 2 | 0 | No | No |
| 17691658 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | March 2022 | May 2023 | Allow | 15 | 1 | 0 | No | No |
| 17641606 | METHODS AND MATERIALS FOR INCREASING LEVEL OF PHOSPHORYLATED AMPK PROTEIN | March 2022 | March 2025 | Allow | 37 | 1 | 1 | No | No |
| 17675453 | PLINABULIN COMPOSITIONS | February 2022 | February 2024 | Allow | 24 | 1 | 0 | No | No |
| 17592679 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | February 2022 | February 2024 | Allow | 25 | 1 | 0 | No | No |
| 17582774 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | January 2022 | February 2023 | Allow | 12 | 0 | 0 | No | No |
| 17625244 | Compounds And Methods For Treating Fibrotic Pathologies | January 2022 | December 2024 | Allow | 36 | 1 | 0 | No | No |
| 17568530 | ETHYNYL DERIVATIVES | January 2022 | July 2024 | Allow | 30 | 2 | 0 | No | No |
| 17564850 | COMPOUND, COMPOSITIONS, AND METHODS | December 2021 | April 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17563351 | Protein Kinase C Beta Inhibitors and Uses Thereof | December 2021 | May 2024 | Abandon | 29 | 3 | 0 | No | No |
| 17561032 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | December 2021 | July 2023 | Allow | 19 | 0 | 0 | No | No |
| 17552649 | Thermally Activated Delayed Fluorescent Material Based on 9,10-Dihydro-9,9-dimethylacridine Analogues for Prolonging Device Longevity | December 2021 | February 2024 | Allow | 26 | 1 | 0 | No | No |
| 17547967 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | December 2021 | March 2025 | Allow | 39 | 1 | 1 | No | No |
| 17541924 | Methods and compositions for the treatment of IL13Ra2- overexpressing cancer | December 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KIFLE, BRUCK.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 53.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner KIFLE, BRUCK works in Art Unit 1624 and has examined 1,899 patent applications in our dataset. With an allowance rate of 81.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 19 months.
Examiner KIFLE, BRUCK's allowance rate of 81.9% places them in the 47% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KIFLE, BRUCK receive 1.44 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KIFLE, BRUCK is 19 months. This places the examiner in the 91% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +14.8% benefit to allowance rate for applications examined by KIFLE, BRUCK. This interview benefit is in the 57% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 35.1% of applications are subsequently allowed. This success rate is in the 73% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 71.3% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 95.7% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 74.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 52.8% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.6% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.